SAN ANTONIO, Texas, February 17, 2026--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.

In a significant advancement for thoracic oncology within the Appalachian region, WVU Medicine has announced it is the first ...

Fortis Hospital Bannerghatta Road has achieved a significant medical milestone by successfully performing Karnataka’s first navigation-based bronchoscopy and lung biopsy, enabling early diagnosis ...

A state-led AI screening drive flags hidden tumours early and sparks national scale-up talks ...

FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Across the spectrum of human afflictions—from cancer to heart disease to rare genetic conditions—medical investigators are continually attempting to break new ground by developing better methods of ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I will be your conference ...

The five-year survival rate for lung cancer is around 56% when it is detected while the cancer is still localized. But few cancers are caught at this early stage. To improve survival rates and patient ...

About a decade later, the U.S. Preventive Services Taskforce (USPSTF) issued updated guidelines recommending annual screening for lung cancer with low-dose CT for adults ages 50 to 80 years with a 20 ...

A female in her 70s was referred to the endocrine surgery unit with a 22 mm right thyroid nodule that was incidentally identified on CT. Cytology from an ultrasound-guided fine needle aspirate ...

Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.